Nuvilex, Inc., an emerging healthcare consumer products company, announced earlier today that it has renewed its Master Distribution Agreement with MedX, Inc., a provider of office-based surgical and aesthetic solutions, for the distribution and sale of its Talsyn Scar Cream through physicians offices.

According to the press release, the one-year renewal provides MedX with an increased distributor margin, allowing a more aggressive and sustained marketing promotion effort. In addition, the minimum order size has been increased 500% from 1,000 units to 5,000 units. Nuvilex and MedX have also agreed to lower the pricing for Talsyn to $29.95 from $65.00. The pricing change is anticipated to enhance Talsyn’s competitive positioning relative to other major scar treatment brands.

“Since 2006, MedX has worked diligently to establish a physician’s office sales base for Talsyn,” stated Martin Schmieg, Chairman and Chief Executive. “The scar treatment market is a highly competitive market. We renewed our distribution agreement with MedX in order further leverage the Talsyn franchise they have created. The higher margins for MedX and a more competitively priced product should translate to more aggressive marketing of our product, which we believe will result in increased sales of Talsyn by the fall of 2009.”